Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Marina Alexandre, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, Catherine Prost-Squarcioni
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2022-04-01
Reeks:Frontiers in Immunology
Onderwerpen:
omalizumab (Xolair)
mucous membrane pemphigoid (MMP)
bullous pemphigoid (BP)
autoimmune bullous diseases (AIBDs)
autoimmune skin diseases
Immunoglobulin E (IgE)
Online toegang:https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items